Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0001430 (adenoma)
 21,222 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The practicability and tolerability of trilostane, a competitive inhibitor of 3 beta-hydroxysteroid-delta 5-dehydrogenase, for the therapy of primary aldosteronism was assessed in 1 patient with aldosterone-producing adenoma (APA) and 3 subjects with idiopathic adrenal hyperplasia (IHA). Trilostane afforded reduction of plasma levels of aldosterone, progesterone, deoxycorticosterone, 17-OH progesterone, cortisol, delta 4-androstenedione, and urinary excretion of 17-hydroxycorticosteroid. Conversely, circulating levels of dehydroepiandrosterone, dehydroepiandrosterone sulfate, and urinary excretion of 17-ketosteroids were increased following this drug therapy. Suppression of mineralo- or glucocorticoid biosynthesis was accompanied by an increase in plasma renin activity. One patient with APA or 3 subjects with IHA showed slight or remarkable improvement of hypertension and hypokalemia. Based on these findings, efficacy and tolerability of trilostane appear to aid in the treatment of IHA.
 ...
PMID:Primary aldosteronism treated by trilostane (3 beta-hydroxysteroid dehydrogenase inhibitor). 298 27

An aldosterone-producing adenoma (APA) was associated with chronic renal failure. Following treatment with Trilostane (a 3 beta-hydroxysteroid dehydrogenase inhibitor), furosemide and continuous ambulatory peritoneal dialysis (CAPD), a left adrenal adenoma was successfully removed. This patient, still being treated with CAPD, is a unique example of primary aldosteronism without showing suppressed plasma renin activity.
 ...
PMID:Primary aldosteronism associated with chronic renal failure. Report of a case. 646 82

A 58-year-old man with primary aldosteronism associated with chronic chronic renal failure was treated with CAPD, oral administrations of Trilostane and furosemide. No adverse clinical or laboratory response could be attributed to these combination therapies. After subsequent removal of aldosterone-producing adenoma from left adrenal gland, his clinical symptoms were slightly improved. This case, still received CAPD treatment, is a unique presentation for primary aldosteronism without showing suppressed plasma renin activity.
 ...
PMID:[Therapeutic experience of primary aldosteronism associated with chronic renal failure]. 664 11

Trilostane is a competitive inhibitor of the 3 beta-hydroxysteroid dehydrogenase enzyme system localized in the adrenal cortex and in the gonads. This inhibitor reduces the production of cortisol, aldosterone and androstendione. Trilostane was used for the treatment of 3 male and 2 female patients with primary aldosteronism, two of whom had an adenoma of the adrenal cortex and three bilateral adrenal hyperplasia. After a 12 weeks' treatment with trilostane (average dosage 288 mg/day) normalization of plasma aldosterone (from 368 to 35.1 pg/ml) was achieved. Average blood pressure had almost normalized (147/98 mm Hg) after the treatment period. However, in one patient no, or only a minor, reduction in blood pressure was observed during trilostane and even during captopril and minoxidil administration. Except slight diarrhea in 2 cases, which did not require cessation of trilostane medication, there were no further side effects. After 12 weeks' treatment the average serum cortisol was in the lower normal range. It is concluded from these results that trilostane is an effective therapeutic agent in primary aldosteronism, especially where there is no indication for surgery.
 ...
PMID:[Therapy of primary aldosteronism with trilostane]. 665 19